Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. [electronic resource]
- The American journal of gastroenterology Nov 2000
- 3326-7 p. digital
Publication Type: Letter
0002-9270
10.1111/j.1572-0241.2000.03325.x doi
Adult Antibodies, Monoclonal--therapeutic use Complement C3 Complement C4 Crohn Disease--drug therapy Female Gastrointestinal Agents--therapeutic use Humans Infliximab Male Prospective Studies